Bristol-Myers Squibb

D

Quotes are delayed by 15 minutes

Bristol-Myers Squibb company profile

CEO

Christopher Boerner

Employees

32,500

Headquarters

Route 206 & Province Line Road, Princeton, NJ 08543, US

Sector

Healthcare

Industry

Drug Manufacturers - General

IPO date

1 Jun 1972

Stock exchange

NYSE

ISIN

US1101221083

Website:bms.com

About the company

Bristol-Myers Squibb Company operates as a global biopharmaceutical entity, actively involved in the research, development, licensing, production, and worldwide commercialization of its medicinal portfolio. The company's therapeutic areas span hematology, oncology, cardiovascular health, immunology, fibrotic conditions, neuroscience, and infectious diseases like COVID-19. Its significant pharmaceutical offerings include Revlimid, an oral immunomodulatory agent for multiple myeloma, and Eliquis, an oral anticoagulant crucial for reducing stroke risk and systemic embolism in non-valvular atrial fibrillation, as well as treating deep vein thrombosis and pulmonary embolism. The portfolio also features Opdivo, utilized across various anti-cancer indications; Pomalyst/Imnovid, prescribed for multiple myeloma patients; and Orencia, targeting active rheumatoid arthritis and psoriatic arthritis in adults. Other key therapies are Sprycel, employed in the management of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, indicated for patients with unresectable or metastatic melanoma; and Abraxane, a protein-bound chemotherapy formulation. Furthermore, Bristol-Myers Squibb offers Reblozyl, addressing anemia in adult patients with beta thalassemia; Empliciti, another treatment option for multiple myeloma; and Zeposia, designed to treat relapsing forms of multiple sclerosis. Revolutionary treatments like Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for adult patients battling relapsed or refractory large B-cell lymphoma, are also part of its lineup. Completing its product range are Inrebic, an oral kinase inhibitor specifically for adult myelofibrosis, and Onureg, used in the treatment of adult patients with acute myeloid leukemia (AML). Bristol-Myers Squibb distributes its pharmaceutical products through a diverse network encompassing wholesalers, distributors, pharmacies, retail outlets, hospitals, clinics, and governmental organizations. Founded in 1887 and formerly known as Bristol-Myers Company, the firm maintains its headquarters in New York, New York.

Employees

Bristol-Myers Squibb had about 32,500 employees at the end of fiscal year 2025 (31 December 2025), by its annual report. That is 4.7% fewer than a year before.

Employees at each fiscal year end, as the company reports them in its annual report (10-K); revenue and net income per employee are the fiscal year's over that count.

Who owns Bristol-Myers Squibb

Institutions such as funds, banks and insurers held 85.4% of Bristol-Myers Squibb's shares on 30 June 2026, 2,636 of them reporting holdings to the SEC; the rest is held by individual investors and other shareholders.

How Bristol-Myers Squibb pays its executives

The chief executive was paid 21.88M USD for fiscal 2025, 73% of it in shares and options.

FY2025 · From the company's proxy statements to the SEC: what each named executive was paid for the fiscal year, shares and options at their value when granted. The latest filing

Common questions about Bristol-Myers Squibb